secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kymera Therapeutics, Inc. (KYMR)
CIK:        0001815442
Form:       8-K
Filed at:   2026-06-25T11:10:11+00:00
Accession:  0001193125-26-281817
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kymera completes enrollment in Phase 2b KT-621 AD trial; topline data accelerated to year-end 2026
--------------------------------------------------------------------------------

- Enrollment in BROADEN2 completed nearly six months ahead of schedule; topline data now expected by year-end 2026.
- Phase 3 trials in atopic dermatitis planned to initiate by mid-2027, subject to regulatory discussions.
- BROADEN2 is a randomized, double-blind, placebo-controlled trial in ~200 patients ages 12-75 over 16 weeks.
- KT-621 also in BREADTH Phase 2b asthma trial with data expected in late 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1815442/000119312526281817/0001193125-26-281817-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1815442/000119312526281817/d62555d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-281817

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer